We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Bristol Myers (BMY) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
The upcoming report from Bristol Myers Squibb (BMY - Free Report) is expected to reveal quarterly earnings of $1.44 per share, indicating a decline of 20% compared to the year-ago period. Analysts forecast revenues of $10.92 billion, representing a decline of 2.5% year over year.
The consensus EPS estimate for the quarter has been revised 0.7% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Bristol Myers metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Sales- Eliquis' of $3.79 billion. The estimate indicates a year-over-year change of +6.2%.
The combined assessment of analysts suggests that 'Net Sales- Orencia' will likely reach $769.38 million. The estimate indicates a year-over-year change of -0.1%.
Analysts' assessment points toward 'Net Sales- Sprycel' reaching $61.90 million. The estimate indicates a year-over-year change of -64.6%.
According to the collective judgment of analysts, 'Net Sales- Reblozyl' should come in at $590.16 million. The estimate indicates a change of +23.5% from the prior-year quarter.
Analysts forecast 'Net Sales- Abraxane- U.S.' to reach $20.14 million. The estimate indicates a year-over-year change of -49.7%.
Analysts expect 'Net Sales- Opdivo- U.S.' to come in at $1.27 billion. The estimate indicates a change of -4.8% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Pomalyst/Imnovid- U.S.' will reach $345.88 million. The estimate points to a change of -35.6% from the year-ago quarter.
Analysts predict that the 'Net Sales- Pomalyst/Imnovid- International' will reach $56.63 million. The estimate indicates a change of -53.6% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Revlimid- U.S.' will reach $167.49 million. The estimate suggests a change of -79.3% year over year.
The average prediction of analysts places 'Net Sales- Revlimid- International' at $68.36 million. The estimate points to a change of -46.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- Reblozyl- U.S.' should arrive at $457.95 million. The estimate suggests a change of +17.4% year over year.
The consensus estimate for 'Net Sales- Reblozyl- International' stands at $119.44 million. The estimate points to a change of +34.2% from the year-ago quarter.
Over the past month, shares of Bristol Myers have returned +0.3% versus the Zacks S&P 500 composite's +9.3% change. Currently, BMY carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Bristol Myers (BMY) Q1 Earnings, Beyond Revenue and EPS
The upcoming report from Bristol Myers Squibb (BMY - Free Report) is expected to reveal quarterly earnings of $1.44 per share, indicating a decline of 20% compared to the year-ago period. Analysts forecast revenues of $10.92 billion, representing a decline of 2.5% year over year.
The consensus EPS estimate for the quarter has been revised 0.7% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Bristol Myers metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Sales- Eliquis' of $3.79 billion. The estimate indicates a year-over-year change of +6.2%.
The combined assessment of analysts suggests that 'Net Sales- Orencia' will likely reach $769.38 million. The estimate indicates a year-over-year change of -0.1%.
Analysts' assessment points toward 'Net Sales- Sprycel' reaching $61.90 million. The estimate indicates a year-over-year change of -64.6%.
According to the collective judgment of analysts, 'Net Sales- Reblozyl' should come in at $590.16 million. The estimate indicates a change of +23.5% from the prior-year quarter.
Analysts forecast 'Net Sales- Abraxane- U.S.' to reach $20.14 million. The estimate indicates a year-over-year change of -49.7%.
Analysts expect 'Net Sales- Opdivo- U.S.' to come in at $1.27 billion. The estimate indicates a change of -4.8% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Pomalyst/Imnovid- U.S.' will reach $345.88 million. The estimate points to a change of -35.6% from the year-ago quarter.
Analysts predict that the 'Net Sales- Pomalyst/Imnovid- International' will reach $56.63 million. The estimate indicates a change of -53.6% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Revlimid- U.S.' will reach $167.49 million. The estimate suggests a change of -79.3% year over year.
The average prediction of analysts places 'Net Sales- Revlimid- International' at $68.36 million. The estimate points to a change of -46.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- Reblozyl- U.S.' should arrive at $457.95 million. The estimate suggests a change of +17.4% year over year.
The consensus estimate for 'Net Sales- Reblozyl- International' stands at $119.44 million. The estimate points to a change of +34.2% from the year-ago quarter.
View all Key Company Metrics for Bristol Myers here>>>Over the past month, shares of Bristol Myers have returned +0.3% versus the Zacks S&P 500 composite's +9.3% change. Currently, BMY carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .